Biogen | BIIB - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 64.53B 5.59B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 1.48B 7.23M 2026-06
Amgen USD 51.86B 27M 2026-06
Bayer EUR 31.16B 480M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
Incyte USD 28.42M 994K 2026-06
Merck USD 51.08B 4.41B 2026-06
Moderna USD 597M 6M 2026-06
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.49B 42M 2026-06
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 14.65B 806M 2026-06
Sanofi EUR 12.3B 3.42B 2026-03
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12